the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending

Phase 1

Completed

• Conditions: Androgenetic Alopecia
• Interventions: Other: Placebo; Drug: KX0826

• Registration Number: NCT04502901
• Lead Sponsor: Suzhou Kintor Pharmaceutical Inc,

Brief Summary

The study is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and PK of KX-826 following topical multiple ascending dose administration.

Detailed Description

KX-826 topical solution will be applied to the scalp of healthy male subjects with androgenetic alopecia.

A total of 40 subjects will be evaluated with 32 subjects randomized to receive active drug and 8 subjects randomized to receive placebo in a double-blind fashion (10 subjects in each dose cohort with 8 subjects randomized to receive active drug and 2 subjects randomized to receive placebo for a total of 4 dose cohorts).

Cohort Dose of KX-826 Subjects

1. 2.5 mg QD for 14 days 10 (8 active + 2 placebo)

2. 5 mg QD for 14 days 10 (8 active + 2 placebo)

3. 10 mg QD for 14 days 10 (8 active + 2 placebo)

4. 20 mg QD for 14 days 10 (8 active + 2 placebo)

Dose escalation will not occur until review of the multiple dose safety from the previous dose cohort is completed. Safety assessments will include monitoring of AEs, vital signs (blood pressure, pulse rate, respiratory rate and oral temperature), clinical laboratory findings, 12-lead ECGs, skin irritation assessments and physical examination findings.

Study Timeline

• Study Start: 2020-01-14
• Study First Submitted: 2020-07-31
• Study First Submitted QC: 2020-08-04
• Study First Posted: 2020-08-06
• Primary Completion: 2020-08-11
• Study Completion: 2021-01-15
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-09
• Last Update Posted: 2021-08-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

1. Are capable of giving informed consent and complying with study procedures;
2. Are males between the ages of 18 and 60 years, inclusive;
3. Have a clinical diagnosis of androgenetic alopecia;
4. Considered healthy by the Principal Investigator, based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG and vital signs (systolic blood pressure ≥90 and ≤150 mmHg, diastolic blood pressure ≥50 and ≤95 mmHg and pulse rate ≥45 and ≤100 bpm; one repeat allowed to confirm out of range values);
5. Have normal renal and hepatic function as determined by the screening laboratory results;
6. Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6 months before screening;
7. Body mass index (BMI) of 19.0 to 35.0 kg/m2 inclusive and body weight not less than 50 kg;
8. Willing and able to adhere to study restrictions and to be confined at the CRU

Exclusion Criteria

1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity;
2. Any visible skin disease, damage or condition at the application site which, in the opinion of the investigator, could compromise subject safety and/or interfere with the evaluation of the test site reaction;
3. Subject has any dermatological disorders of the scalp;
4. Subject has a history of hair transplants, hair weaves;
5. Subject has hypersensitivity to previously prescribed minoxidil or finasteride;
6. Known or suspected malignancy;
7. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody;
8. A hospital admission or major surgery within 30 days prior to screening;
9. Participation in any other investigational drug trial within 30 days prior to screening;
10. A history of prescription drug abuse, or illicit drug use within 6 months prior to screening;
11. A history of alcohol abuse according to medical history within 6 months prior to screening;
12. A positive screen for alcohol or drugs of abuse;
13. Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or blood products) or acute loss of blood during the 90 days prior to screening;
14. Use of prescription or over-the-counter (OTC) medications, and herbal (including St John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use of acetaminophen at <3g/day is permitted until 24 hours prior to dosing);
15. An unwillingness of male participants to use appropriate contraceptive measures if engaging in sexual intercourse with a female partner of childbearing potential. Appropriate measures include use of a condom and spermicide and, for female partners, use of an intrauterine device (IUD), diaphragm with spermicide, oral contraceptives, injectable progesterone, progesterone subdermal implants, or a tubal ligation.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control Group- Placebo	Placebo	Placebo is tropically applied to the scalp of healthy male subjects once a day for 14 days.
Experimental Group -KX0826	KX0826	KX0826 is tropically applied to the scalp of healthy male subjects once a day for 14 days. The applied dosage cohorts are 2.5mg, 5mg, 10mg and 20mg.

Primary Outcome Measures

Name	Time	Method
Incidence of treatment-emergent adverse events (TEAE) by skin irritation assessment, vital sign, ECG and clinical lab assessments	19 days	skin irritation assessment will be performed during the treatment period. The dermal response score will be based on a visual irritation scale (0-7) that rates the degree of erythema, edema and other signs of cutaneous irritation. abnormal vital sign (including blood pressure, pulse rate, respiratory rate and oral temperatures), 12-lead ECG, hematology (hemoglobin, hematocrit, platelet count, RBC count, WBC count, with differential), blood chemistry (BUN, creatinine, total bilirubin, alkaline phosphatase, AST, ALT, GGT, LDH, glucose, albumin, total protein, bicarbonate, phosphate, sodium, potassium, chloride, calcium, total cholesterol, uric acid) and urinalysis (pH, specific gravity, protein, glucose, ketones, bilirubin, blood, nitrites, leukocytes, urobilinogen, microscopic urine analysis on abnormal findings) during the treatment period will be recorded and reported.
Incidence of study drug related TEAEs	19 days	incidence of study drug related TEAEs (possibly, probably or definitely)

Secondary Outcome Measures

Name	Time	Method
AUC from time 0 to the last non-zero concentration (AUClast)	19 days	Pharmacokinetics
Area under the concentration curve for on dosing interval at steady state (AUC0-t)	19 days	Pharmacokinetics
Cmax at steady state (Cmax_ss)	19 days	Pharmacokinetics
Maximum observed concentration (Cmax)	1 day	Pharmacokinetics
Time at which Cmax was first observed (Tmax)	1 day	Pharmacokinetics
Area under the concentration curve from time 0 hour to 24 hour (AUC0-24)	1 day	Pharmacokinetics
AUC from time 0 and extrapolated to infinite time, total exposure (AUCinf)	19 days	Pharmacokinetics
Terminal elimination rate constant (Kel)	19 days	Pharmacokinetics
Time at which Cmax_ss was first observed (Tmax_ss)	19 days	Pharmacokinetics
Minimum observed or "trough" concentration at steady state (Cmin_ss)	19 days	Pharmacokinetics
Average concentration at steady state (Cav_ss)	19 days	Pharmacokinetics
Biological half-life (T1/2 el)	19 days	Pharmacokinetics

Trial Locations

Locations (1)

inVentiv Health Clinical Research Services LLC; 🇺🇸 Miami, Florida, United States